کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
2710385 | 1144998 | 2007 | 6 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
Cancer bronchique non à petites cellules : du traitement de la rechute aux traitements des rechutes
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
کلمات کلیدی
موضوعات مرتبط
علوم پزشکی و سلامت
پزشکی و دندانپزشکی
کاردیولوژی و پزشکی قلب و عروق
پیش نمایش صفحه اول مقاله
چکیده انگلیسی
Second line treatments of non-small cell lung cancer are currently largely used because of their effectiveness in terms of survival and quality of life. Three drugs are currently licensed for this indication (docetaxel, pemetrexed and erlotinib), and possibly others will follow in the years to come. A true therapeutic strategy can thus be applied in advanced non-small cell lung cancer. The questions which need to be resolved are the optimum choice of treatments (mono-chemotherapy? Poly-chemotherapy? Therapeutic biological?) related to the still poorly understood “characteristics” of patients and tumours, as well as the specific question as to whether patients who have received adjuvant chemotherapy and then relapse should receive “first line” or “second line” therapy?
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Revue des Maladies Respiratoires - Volume 24, Issue 8, Part 2, October 2007, Pages 108-113
Journal: Revue des Maladies Respiratoires - Volume 24, Issue 8, Part 2, October 2007, Pages 108-113
نویسندگان
P.-J. Souquet,